智通财经APP讯，中国中药(00570)及要约人国药集团共裕有限公司联合公布，就要约人根据香港法例第622章公司条例第673条通过计划安排的方式将该公司私有化的附先决条件的建议，于2024年10月18日，先决条件(a)(即境外直接投资批准)仍未得到满足，先决条件最后截止日期并未延长。因此，建议于2024年10月18日失效。相应地，计划文件将不会寄发，且股份在香港联交所的上市地位将不会撤销。
有关建议的要约期已于本联合公告日期结束。根据收购守则规则31.1，惟获执行人员同意除外，要约人或要约人一致行动人(或其后与彼等任何一方一致行动的任何人)，概不得于建议遭撤回或失效日期起计12个月内，宣布对该公司作出要约或可能作出要约，或收购公司的任何投票权，以至于要约人或要约人一致行动人会因此而须根据收购守则规则26作出要约。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.